Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02376985
Recruitment Status : Recruiting
First Posted : March 3, 2015
Last Update Posted : August 2, 2017
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Comprehensive Support Project for Oncology Research

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : March 31, 2019
  Estimated Study Completion Date : May 31, 2019